REPL
NASDAQ HealthcareReplimune Group, Inc. - Common Stock
Biotechnology
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
�� 市场数据
| 价格 | $8.87 |
|---|---|
| 成交量 | 6,202,273 |
| 市值 | 732.42M |
| 贝塔系数 | 0.120 |
| RSI（14日） | 79.5 超买 |
| 200日均线 | $6.83 |
| 50日均线 | $4.80 |
| 52周最高 | $13.24 |
| 52周最低 | $1.50 |
| Forward P/E | -4.30 |
| Price / Book | 3.35 |
🎯 投资策略评分
REPL 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🎈 Over-Hyped (94/100) — 此策略 超买股票（潜在做空标的）.
评分最低的策略： 🚀 Moon Shot (2/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 REPL in your text
粘贴任何文章、记录或帖子 — 工具将提取 REPL 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-06-02.